Intra-Cellular Therapies Beheer
Beheer criteriumcontroles 3/4
De CEO Intra-Cellular Therapies is Sharon Mates, benoemd in May2002, heeft een ambtstermijn van 22.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 10.09M, bestaande uit 8.8% salaris en 91.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.01% van de aandelen van het bedrijf, ter waarde $ 95.73M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.1 jaar en 10.8 jaar.
Belangrijke informatie
Sharon Mates
Algemeen directeur
US$10.1m
Totale compensatie
| Percentage CEO-salaris | 8.8% |
| Dienstverband CEO | 22.5yrs |
| Eigendom CEO | 1.0% |
| Management gemiddelde ambtstermijn | 6.1yrs |
| Gemiddelde ambtstermijn bestuur | 10.8yrs |
Recente managementupdates
Recent updates
Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26%
Nov 07
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business
Sep 22Peaking Back In On Intra-Cellular Therapies
Sep 04Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 10With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For
Jul 27Intra-Cellular Brightens MDD Outlook With Caplyta Success
Jun 19Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data
Apr 16Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark
Apr 09We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Mar 17Intra-Cellular Therapies Is On Fire
Mar 11Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'
Feb 11Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues
Dec 24We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Nov 11Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth
Aug 07Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation
May 09After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar
Apr 17We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate
Jan 31Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans
Oct 25Intra-Cellular Therapies: What Lies Ahead
Sep 20Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug
Aug 22Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M
Aug 09We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely
Jul 09Intra-Cellular Therapies: A Dramatic Story
Jun 18Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth
Apr 03Intra-Cellular: Not Participating In A Bear Market
Mar 31Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand
Mar 08Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$86m |
| Jun 30 2024 | n/a | n/a | -US$84m |
| Mar 31 2024 | n/a | n/a | -US$111m |
| Dec 31 2023 | US$10m | US$892k | -US$140m |
| Sep 30 2023 | n/a | n/a | -US$155m |
| Jun 30 2023 | n/a | n/a | -US$184m |
| Mar 31 2023 | n/a | n/a | -US$228m |
| Dec 31 2022 | US$9m | US$849k | -US$256m |
| Sep 30 2022 | n/a | n/a | -US$298m |
| Jun 30 2022 | n/a | n/a | -US$321m |
| Mar 31 2022 | n/a | n/a | -US$304m |
| Dec 31 2021 | US$7m | US$794k | -US$284m |
| Sep 30 2021 | n/a | n/a | -US$259m |
| Jun 30 2021 | n/a | n/a | -US$237m |
| Mar 31 2021 | n/a | n/a | -US$232m |
| Dec 31 2020 | US$5m | US$767k | -US$227m |
| Sep 30 2020 | n/a | n/a | -US$207m |
| Jun 30 2020 | n/a | n/a | -US$187m |
| Mar 31 2020 | n/a | n/a | -US$160m |
| Dec 31 2019 | US$5m | US$745k | -US$148m |
| Sep 30 2019 | n/a | n/a | -US$148m |
| Jun 30 2019 | n/a | n/a | -US$155m |
| Mar 31 2019 | n/a | n/a | -US$154m |
| Dec 31 2018 | US$4m | US$723k | -US$155m |
| Sep 30 2018 | n/a | n/a | -US$145m |
| Jun 30 2018 | n/a | n/a | -US$126m |
| Mar 31 2018 | n/a | n/a | -US$106m |
| Dec 31 2017 | US$5m | US$702k | -US$98m |
Compensatie versus markt: De totale vergoeding ($USD 10.09M ) Sharon } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 7.98M ).
Compensatie versus inkomsten: De vergoeding van Sharon is gestegen terwijl het bedrijf verliesgevend is.
CEO
Sharon Mates (71 yo)
22.5yrs
Tenure
US$10,086,413
Compensatie
Dr. Sharon Mates, Ph.D. co-founded Intra-Cellular Therapies, Inc. (a/k/a ITI) in May 2002 and was its President until March 19, 2024. She has been Chairman and Chief Executive Officer of Intra-Cellular The...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 22.5yrs | US$10.09m | 1.01% $ 95.7m | |
| President | less than a year | US$3.53m | 0% $ 0 | |
| Executive VP & Chief Medical Officer | 6.3yrs | US$3.51m | 0.019% $ 1.8m | |
| EVP & Chief Commercial Officer | 6.1yrs | US$3.54m | 0.028% $ 2.7m | |
| Senior VP & Chief Scientific Officer | 9yrs | US$2.13m | geen gegevens | |
| Vice President of Corporate Communications & Investor Relations | 10.7yrs | US$1.38m | geen gegevens | |
| Senior VP & Chief Compliance Officer | 5.3yrs | geen gegevens | geen gegevens | |
| Senior Vice President | no data | geen gegevens | geen gegevens | |
| Senior VP & Head of Regulatory Affairs | 6.2yrs | geen gegevens | geen gegevens | |
| Senior VP of Market Access | 5.7yrs | geen gegevens | geen gegevens | |
| Senior VP & Head of Clinical Development | 2.6yrs | geen gegevens | geen gegevens |
6.1yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ITCI is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.1 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 11.3yrs | US$10.09m | 1.01% $ 95.7m | |
| Independent Director | 10.8yrs | US$470.51k | 0.11% $ 10.5m | |
| Lead Independent Director | 10.8yrs | US$507.58k | 0.011% $ 1.0m | |
| Independent Director | 11.3yrs | US$473.34k | 0.039% $ 3.7m | |
| Chairman of Medical Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Medical Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Medical Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Medical Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Medical Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 2.6yrs | US$461.30k | 0.0015% $ 140.3k |
10.8yrs
Gemiddelde duur
71yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ITCI zijn ervaren en ervaren (gemiddelde ambtstermijn van 10.8 jaar).